Vaccines are urgently needed to combat the global coronavirus disease 2019 (COVID-19)
pandemic, and testing of candidate vaccines in an appropriate non-human primate (NHP) …

Mycobacterium tuberculosis lung infection results in a complex multicellular structure: the
granuloma. In some granulomas, immune activity promotes bacterial clearance, but in others, …

Trials to test new drugs currently in development against tuberculosis in humans are
impractical. All animal models to prioritize new regimens are imperfect, but nonhuman primates (…

Bacille Calmette-Guerin (BCG), the only approved Mycobacterium tuberculosis (Mtb) vaccine,
provides limited durable protection when administered intradermally. However, recent …

Cynomolgus macaques infected with low-dose Mycobacterium tuberculosis develop both
active tuberculosis and latent infection similar to those of humans, providing an opportunity to …

Existing small-animal models of tuberculosis (TB) rarely develop cavitary disease, limiting
their value for assessing the biology and dynamics of this highly important feature of human …

Mycobacterium tuberculosis infection presents across a spectrum in humans, from latent
infection to active tuberculosis. Among those with latent tuberculosis, it is now recognized that …

The functional role of CD8 + lymphocytes in tuberculosis remains poorly understood. We
depleted innate and/or adaptive CD8 + lymphocytes in macaques and showed that loss of all …

Tuberculosis, caused by Mycobacterium tuberculosis (Mtb), is the most common cause of
death in people living with human immunodeficiency virus (HIV). Intra-dermal Bacille Calmette–…

Mycobacterium tuberculosis remains the number one infectious agent in the world today.
With the emergence of antibiotic resistant strains, new clinically relevant methods are needed …